AbbVie Inc. $ABBV Shares Sold by Capital Investment Advisory Services LLC

Key Points

• Capital Investment Advisory Services LLC cut its AbbVie stake by 24.4% in the second quarter, selling 11,302 shares and retaining 35,075 shares valued at approximately $8.83 million.
• Institutional ownership remains substantial at 70.23%, with several major investors—including Norges Bank, Wellington Management, Capital World Investors and Geode Capital—recently increasing their positions.
• AbbVie exceeded quarterly earnings and revenue expectations, reporting $3.65 in EPS and $16.99 billion in revenue. Analysts maintain a “Moderate Buy” consensus with an average price target of $275.73, while the company pays a quarterly dividend of $1.73 per share.

Capital Investment Advisory Services LLC lessened its holdings in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 24.4% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 35,075 shares of the company's stock after selling 11,302 shares during the period. Capital Investment Advisory Services LLC's holdings in AbbVie were worth $8,826,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in ABBV. Norges Bank acquired a new stake in AbbVie during the 4th quarter worth about $5,865,055,000. Wellington Management Group LLP boosted its stake in shares of AbbVie by 457.4% in the third quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company's stock worth $2,439,714,000 after buying an additional 8,646,424 shares during the last quarter. Capital World Investors boosted its stake in shares of AbbVie by 106.3% in the fourth quarter. Capital World Investors now owns 13,071,444 shares of the company's stock worth $2,986,777,000 after buying an additional 6,736,161 shares during the last quarter. Cardano Risk Management B.V. grew its holdings in AbbVie by 914.6% during the fourth quarter. Cardano Risk Management B.V. now owns 5,444,930 shares of the company's stock worth $1,244,112,000 after acquiring an additional 4,908,260 shares during the period. Finally, Geode Capital Management LLC grew its holdings in AbbVie by 10.4% during the fourth quarter. Geode Capital Management LLC now owns 44,629,980 shares of the company's stock worth $10,179,099,000 after acquiring an additional 4,190,487 shares during the period. 70.23% of the stock is currently owned by institutional investors and hedge funds.

AbbVie Price Performance

Shares of ABBV stock opened at $250.53 on Tuesday. AbbVie Inc. has a 1-year low of $190.75 and a 1-year high of $267.47. The company has a market cap of $442.63 billion, a price-to-earnings ratio of 70.77, a PEG ratio of 0.83 and a beta of 0.30. The stock has a 50 day simple moving average of $245.49 and a 200-day simple moving average of $226.35.

AbbVie (NYSE:ABBV - Get Free Report) last released its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.61 by $0.04. The firm had revenue of $16.99 billion for the quarter, compared to analysts' expectations of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The firm's revenue for the quarter was up 10.2% compared to the same quarter last year. During the same quarter last year, the company earned $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Analysts anticipate that AbbVie Inc. will post 14.07 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, August 14th. Investors of record on Wednesday, July 15th were given a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 2.8%. The ex-dividend date was Wednesday, July 15th. AbbVie's dividend payout ratio is 195.48%.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on ABBV. Wolfe Research raised shares of AbbVie from a "peer perform" rating to an "outperform" rating and set a $300.00 price objective on the stock in a research note on Thursday. Citigroup increased their price target on shares of AbbVie from $230.00 to $260.00 and gave the stock a "neutral" rating in a report on Wednesday, July 15th. Wall Street Zen lowered shares of AbbVie from a "strong-buy" rating to a "buy" rating in a research report on Sunday, July 5th. Evercore set a $235.00 price objective on shares of AbbVie in a report on Friday, May 15th. Finally, Wells Fargo & Company increased their target price on shares of AbbVie from $295.00 to $300.00 and gave the stock an "overweight" rating in a research note on Monday. Two research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $275.73.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source